Common blood pressure drug could make cancer therapy far more powerful

Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer drug olaparib, potentially expanding its benefits beyond patients with BRCA-related tumors. The combination is already being tested in human clinical trials after showing strong immune-boosting and anticancer effects in preclinical studies.